Molecular Cancer Therapeutics · 2006 · 45 citations · 42 references
PharmacyMedicinal ChemistryPharmacologyCancer PharmacologyDrug DeliveryDrug DiscoveryAnticancer Prodrug DesignCytotoxic ChemotherapyDrug DispositionEnzyme InhibitionOncology PharmacologyAnticancer ActivityAnticancer ChemotherapyChemotherapeutic Prodrug DesignNitroaromatic ProdrugsSuspensionsTubulin Polymerization Inhibitors
Nitrothienylprop-2-yl ether formation on the 3'-phenolic position of combretastatin A-4 (1) abolishes the cytotoxicity and tubulin polymerization-inhibitory effects of the drug. 5-Nitrothiophene derivatives of 1 were synthesized following model kinetic studies with analogous coumarin derivatives, and of these, compound 13 represents a promising new lead in bioreductively targeted cytotoxic anticancer therapies. In this compound, optimized gem-dimethyl alpha-carbon substitution enhances both the aerobic metabolic stability and the efficiency of hypoxia-mediated drug release. Only the gem-substituted derivative 13 released 1 under anoxia in either in vitro whole-cell experiments or supersomal suspensions. The rate of release of 1 from the radical anions of these prodrugs is enhanced by greater methyl substitution on the alpha-carbon. Cellular and supersomal studies showed that this alpha-substitution pattern controls the useful range of oxygen concentrations over which 1 can be effectively released by the prodrug.
42
Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature.
G. Dark, S A Hill, Vivien E. Prise et al. · PubMed · 1997 · 624 citations
Medicine, Oncology, Pharmacology +13
Afshin Dowlati, Kelly M. Robertson, Matthew M. Cooney et al. · PubMed · 2002 · 406 citations
Medicine, Oncology, Pharmacology +17